AstraZeneca PLC (AZN)vsWaystar Holding Corp. Common Stock (WAY)
AZN
AstraZeneca PLC
$172.48
+0.48%
HEALTHCARE · Cap: $261.94B
WAY
Waystar Holding Corp. Common Stock
$23.69
+2.44%
HEALTHCARE · Cap: $4.24B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 5125% more annual revenue ($60.44B vs $1.16B). AZN leads profitability with a 17.2% profit margin vs 10.9%. AZN trades at a lower P/E of 25.4x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
WAY
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.0%
Fair Value
$194.22
Current Price
$172.48
$21.74 discount
Intrinsic value data unavailable for WAY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 25.6%
Revenue surging 22.4% year-over-year
Earnings expanding 37.5% YoY
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Premium valuation, high expectations priced in
ROE of 3.2% — below average capital efficiency
Weak financial health signals
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : WAY
The strongest argument for WAY centers on Price/Book, Operating Margin, Revenue Growth. Revenue growth of 22.4% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : WAY
The primary concerns for WAY are P/E Ratio, Return on Equity, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while WAY is a growth play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.23 — expect wider price swings.
WAY is growing revenue faster at 22.4% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 63/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Waystar Holding Corp. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Waystar Holding Corp. The company is headquartered in Lehi, Utah.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?